Update shared on15 Aug 2025
With no change in underlying revenue growth forecasts or discount rate, analysts maintained their consensus price target for Kopin at $2.42.
What's in the News
- Kopin secured a $9 million follow-on production contract for custom thermal imaging assemblies supporting a major U.S. defense contractor’s man portable weapon system.
- The company entered into a $7 million private placement of convertible preferred shares with Theon International Plc, subject to regulatory approval.
- Erich Manz was appointed Chief Financial Officer, succeeding retiring CFO Rich Sneider.
- Kopin received a contract update for Phase 2 of the Next-Generation Short-Range Interceptor Visual Display Subsystem from Lockheed Martin, involving delivery of high-resolution OLED microdisplay assemblies.
- In partnership with HMDmd, Kopin delivered the first CR3 wearable surgical monitor to Carl Zeiss Meditec, strengthening its position in the medical-grade display market.
Valuation Changes
Summary of Valuation Changes for Kopin
- The Consensus Analyst Price Target remained effectively unchanged, at $2.42.
- The Consensus Revenue Growth forecasts for Kopin remained effectively unchanged, at 20.1% per annum.
- The Discount Rate for Kopin remained effectively unchanged, at 10.12%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.